Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...

Great hopes rest on a product from the French-Austrian company Valneva. However, a vaccine from U.S. company Novavax, also based on proven technology, may reach more markets this winter.